Research Library

198 published studies and registered trials on the compounds in our catalog, collected worldwide from PubMed, Europe PMC, journal publishers, J-STAGE (Japan), Chinese Biological Abstracts and the ClinicalTrials.gov registry. Each entry links to the original record and notes the study model (in vitro, animal, human or registered trial) and, where it applies, the article language.

Scientific reference onlyCitations are provided for scientific reference only. USAPI products are for research use only and are not for human or veterinary use. The cited studies did not use USAPI products, and no claims are made or implied about USAPI products.

BPC-157 + TB-500 (combination)

Studies that examined BPC-157 and TB-500 together.

Catalog items: BPC-157 / TB-500 Blend 10 mg + 10 mg

Animal (rat) — Türkiye

Biçer O et al. Jt Dis Relat Surg. 2026;37(3):822-837. PMID 42542926 · DOI 10.52312/jdrs.2026.2951
Rat Achilles tendon injury model comparing BPC-157, TB-500 and their combination using biomechanical, histopathological and immunohistochemical analyses.

BPC-157

Synthetic pentadecapeptide (BPC 157). Published work is predominantly rodent and in vitro; human data are limited to small uncontrolled reports.

Catalog items: BPC-157 10 mg, BPC-157 / TB-500 Blend 10 mg + 10 mg

Animal (rat) + in vitro

Staresinic M et al. J Orthop Res. 2003;21(6):976-83. PMID 14554208 · DOI 10.1016/S0736-0266(03)00110-4
Rat model of surgically transected Achilles tendon examined with functional, macroscopic and histologic measures, with a parallel in vitro assay of cultured tendocytes.
In vitro (rat cells)

Chang CH et al. J Appl Physiol (1985). 2011;110(3):774-80. PMID 21030672 · DOI 10.1152/japplphysiol.00945.2010
Cell-culture study of rat Achilles tendon fibroblasts examining outgrowth, survival under oxidative stress and migration, along with FAK-paxillin signaling.
In vitro (rat cells)

Chang CH et al. Molecules. 2014;19(11):19066-77. PMID 25415472 · DOI 10.3390/molecules191119066
Cell-culture study of rat Achilles tendon fibroblasts examining growth hormone receptor expression at the mRNA and protein level and downstream JAK2 signaling.
In vitro + animal (rat)

Hsieh MJ et al. J Mol Med (Berl). 2017;95(3):323-333. PMID 27847966 · DOI 10.1007/s00109-016-1488-y
Angiogenesis assays (chick chorioallantoic membrane, endothelial tube formation) and a rat hind-limb ischemia model examining VEGFR2 expression and signaling.
Animal (rat, dog) — pharmacokinetics

He L et al. Front Pharmacol. 2022;13:1026182. PMID 36588717 · DOI 10.3389/fphar.2022.1026182
Preclinical pharmacokinetic study in rats and beagle dogs describing absorption, tissue distribution, metabolism and excretion of the peptide.
Ex vivo + in vitro

Hsieh MJ et al. Sci Rep. 2020;10(1):17078. PMID 33051481 · DOI 10.1038/s41598-020-74022-y
Isolated rat aorta preparation and cultured endothelial cells examining vasomotor tone and Src–Caveolin-1–eNOS signaling.
Human — retrospective case series

Lee E et al. Altern Ther Health Med. 2021;27(4):8-13. PMID 34324435
Retrospective review of patient records from a single clinic describing intra-articular peptide injections in individuals reporting knee pain; uncontrolled, small sample.
Human — uncontrolled pilot

Lee E et al. Altern Ther Health Med. 2024;30(10):12-17. PMID 39325560
Small open-label pilot study without a control group describing symptom questionnaires in patients with interstitial cystitis.
Animal (rat) — Croatia

Novinscak T et al. Surg Today. 2008;38(8):716-25. PMID 18668315 · DOI 10.1007/s00595-007-3706-2
Rat model of gastrocnemius muscle crush injury examined with functional, macroscopic, microscopic and enzyme measures.
Animal (rat) — Croatia

Krivic A et al. J Orthop Res. 2006;24(5):982-9. PMID 16583442 · DOI 10.1002/jor.20096
Rat model of surgical Achilles tendon detachment from bone, including a corticosteroid co-exposure arm, examined biomechanically and histologically.
Animal (rat) — Türkiye

Yıldırım AK et al. Sci Rep. 2026;16(1). PMID 42204242 · DOI 10.1038/s41598-026-55449-1
Rat model of lower-limb ischemia-reperfusion injury induced by abdominal aortic clamping, with biochemical and histological measures in groups given BPC 157 or saline.
Ex vivo (human arterial tissue) — Türkiye

Yildirim AK et al. J Clin Med. 2026;15(9). PMID 42123221 · DOI 10.3390/jcm15093488
Organ-bath study of residual internal mammary artery segments from bypass surgery, examining vascular tone responses to BPC 157 and the role of endothelial nitric oxide signaling.
Human — uncontrolled pilot (2 participants)

Lee E et al. Altern Ther Health Med. 2025;31(5):20-24. PMID 40131143
Two-participant pilot study recording blood work and vital signs before and after intravenous BPC-157 infusions on consecutive days.
Animal (rat) — Croatia

Matek D et al. Pharmaceutics. 2025;17(1). PMID 39861766 · DOI 10.3390/pharmaceutics17010119
Rat model of surgical quadriceps muscle detachment from bone, followed with functional, macroscopic, microscopic and imaging assessments up to 90 days in groups given BPC 157 or control.
Analytical chemistry (in vitro metabolism) — China

Tian T et al. Molecules. 2023;28(21). PMID 37959764 · DOI 10.3390/molecules28217345
Doping-control study using 13C/15N-labeled BPC-157 and UHPLC high-resolution mass spectrometry to map its in vitro metabolites.
Animal (rat) — Korea

Jung YH et al. J Dent Anesth Pain Med. 2022;22(2):97-105. PMID 35449779 · DOI 10.17245/jdapm.2022.22.2.97
Rat postoperative incisional pain model comparing several BPC-157 groups with saline using mechanical withdrawal thresholds.
Animal (rat) + in vitro — China

Huang T et al. Drug Des Devel Ther. 2015;9:2485-99. PMID 25995620 · DOI 10.2147/DDDT.S82030
Rat alkali-burn skin wound model with topical BPC-157, plus cell proliferation, migration and tube-formation assays in vitro.
Animal (rat, mouse) — Croatia; J-STAGE

Lovric-Bencic M et al. J Pharmacol Sci. 2004;95(1):19-26. PMID 15153646 · DOI 10.1254/jphs.95.19 · J-STAGE
Doxorubicin-induced congestive heart failure model in rats and mice comparing BPC 157 with amlodipine and losartan, measuring big endothelin-1 and plasma enzymes. Published in the Journal of Pharmacological Sciences (Japanese Pharmacological Society).
Animal (rat, mouse) + in vitro — Croatia

Tkalcević VI et al. Eur J Pharmacol. 2007;570(1-3):212-21. PMID 17628536 · DOI 10.1016/j.ejphar.2007.05.072
Comparison of PL 14736 (BPC 157) with PDGF-BB in rat sponge-implant granulation tissue and diabetic-mouse excisional wounds, with egr-1 expression studied in Caco-2 cells.
Animal (rat, mouse) — Croatia; published in China

Sikiric P et al. Acta Pharmacol Sin (Zhongguo Yao Li Xue Bao). 2001;22(3):225-230. Europe PMC (CBA 401738)
Rat shock-probe/burying and mouse light/dark behavioral tests comparing BPC-157 with diazepam and saline. Published in Acta Pharmacologica Sinica; record from Chinese Biological Abstracts.
Registered clinical trial — Phase 1

ClinicalTrials.gov · Phase 1 · Unknown · first posted 2015. NCT02637284
Registered interventional study (Phase 1); registry status: unknown; start 2015-10; locations: Mexico.

TB-500 / Thymosin β4

TB-500 is a synthetic peptide related to the actin-binding region of thymosin β4 (Tβ4). Most peer-reviewed literature studies full-length Tβ4 rather than TB-500 itself; studies of TB-500 / Ac-LKKTETQ are mainly analytical (identification, metabolism, anti-doping).

Catalog items: TB-500 10 mg, BPC-157 / TB-500 Blend 10 mg + 10 mg

Animal (rat)

Malinda KM et al. J Invest Dermatol. 1999;113(3):364-8. PMID 10469335 · DOI 10.1046/j.1523-1747.1999.00708.x
Rat full-thickness dermal wound model examining re-epithelialization, wound contraction, collagen deposition and angiogenesis after topical or intraperitoneal thymosin β4.
In vitro (human cells)

Malinda KM et al. FASEB J. 1997;11(6):474-81. PMID 9194528 · DOI 10.1096/fasebj.11.6.9194528
Cell-culture study of human umbilical vein endothelial cells examining directional migration in chemotaxis assays.
Animal (mouse) + in vitro

Bock-Marquette I et al. Nature. 2004;432(7016):466-72. PMID 15565145 · DOI 10.1038/nature03000
Mouse coronary-ligation model and embryonic cardiac cell cultures examining cell migration, survival and integrin-linked kinase (ILK)/Akt signaling.
Animal (mouse)

Smart N et al. Nature. 2007;445(7124):177-82. PMID 17108969 · DOI 10.1038/nature05383
Mouse study of embryonic heart development and adult epicardial explants examining coronary vessel formation and epicardial progenitor mobilization.
Animal (rat, mouse) + in vitro

Philp D et al. FASEB J. 2004;18(2):385-7. PMID 14657002 · DOI 10.1096/fj.03-0244fje
Rodent study of hair follicle cycling examining follicular stem-cell migration and differentiation, with supporting cell-culture assays.
Human — Phase I clinical trial

Ruff D et al. Ann N Y Acad Sci. 2010;1194:223-9. PMID 20536472 · DOI 10.1111/j.1749-6632.2010.05474.x
Randomized, placebo-controlled, single- and multiple-ascending-dose Phase I study of intravenous synthetic thymosin β4 in healthy volunteers assessing safety, tolerability and pharmacokinetics.
Analytical chemistry

Delcourt V et al. Drug Test Anal. 2023;15(4):458-464. PMID 36482504 · DOI 10.1002/dta.3421
Analytical (mass spectrometry) characterization of commercially sold 'TB500/TB1000' and related products, examining their actual composition versus labeling.
Analytical chemistry — Belgium/Italy

Esposito S et al. Drug Test Anal. 2012;4(9):733-8. PMID 22962027 · DOI 10.1002/dta.1402
Synthesis and high-resolution mass-spectrometric identification of the N-terminal acetylated 17–23 fragment of thymosin β4 (Ac-LKKTETQ) in a product sold as TB-500.
Analytical chemistry — Hong Kong

Ho EN et al. J Chromatogr A. 2012;1265:57-69. PMID 23084823 · DOI 10.1016/j.chroma.2012.09.043
Development of a doping-control method for TB-500 (LKKTETQ) and its metabolites in equine urine and plasma by liquid chromatography–mass spectrometry.
In vitro + animal (rat) — Korea

Rahaman KA et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2024;1235:124033. PMID 38382158 · DOI 10.1016/j.jchromb.2024.124033
Analytical study quantifying TB-500 (Ac-LKKTETQ) and its metabolites in in vitro incubations and in rats by high-resolution mass spectrometry.
In vitro + animal

Sosne G et al. FASEB J. 2010;24(7):2144-51. PMID 20179146 · DOI 10.1096/fj.09-142307
Study mapping which short peptide sequences within thymosin β4 (including the actin-binding LKKTETQ region) account for its activities in cell and animal assays.
Human — Phase I clinical trial (China)

Wang X et al. J Cell Mol Med. 2021;25(17):8222-8228. PMID 34346165 · DOI 10.1111/jcmm.16693
First-in-human randomized, double-blind, placebo-controlled single- and multiple-dose Phase I study of intravenous recombinant human thymosin β4 (NL005) in healthy subjects assessing safety, pharmacokinetics and anti-drug antibodies.
Human — Phase II clinical trial

Sosne G et al. Cornea. 2015;34(5):491-6. PMID 25826322 · DOI 10.1097/ICO.0000000000000379
Small multicenter, randomized, double-masked Phase II study of thymosin β4 eye drops (RGN-259) in patients with severe dry eye, assessing safety and ocular signs and symptoms.
Animal (mouse) + human — China

Zhang Y et al. Cardiovasc Res. 2025;121(17):2747-2758. PMID 41229390 · DOI 10.1093/cvr/cvaf223
Mouse cardiac ischemia/reperfusion and ligation models with in vitro cardiomyocyte assays, plus a clinical cohort of STEMI patients given recombinant human thymosin β4 after PCI.
Peptide chemistry + in vitro (human blood) — Japan

Abiko T et al. Chem Pharm Bull (Tokyo). 1984;32(11):4497-505. PMID 6335841 · DOI 10.1248/cpb.32.4497
Peptide-synthesis study of deacetyl-thymosin β4 by azide fragment condensation, with in vitro incubation of blood from patients with uremia to examine peripheral T-cell subsets.
Human — Phase III randomized trial

Sosne G et al. Int J Mol Sci. 2022;24(1). PMID 36613994 · DOI 10.3390/ijms24010554
Randomized, placebo-controlled, double-masked Phase III trial (SEER-1) of 0.1% RGN-259 (thymosin β4) eye drops in patients with stage 2–3 neurotrophic keratopathy.
Human — randomized trial report (Italy, Poland)

Guarnera G et al. Ann N Y Acad Sci. 2007;1112:407-12. PMID 17495250 · DOI 10.1196/annals.1415.003
Report on a double-blind, placebo-controlled, dose-escalation study of topical thymosin β4 in patients with venous ulcers at 10 sites in Italy and Poland.
Human — case series

Dunn SP et al. Arch Ophthalmol. 2010;128(5):636-8. PMID 20457990 · DOI 10.1001/archophthalmol.2010.53
Case series describing thymosin β4 eye drops in patients with chronic non-healing neurotrophic corneal epithelial defects.
Animal (mouse, rat)

Philp D et al. Wound Repair Regen. 2003;11(1):19-24. PMID 12581423 · DOI 10.1046/j.1524-475x.2003.11105.x
Full-thickness dermal wound studies in diabetic (db/db) and aged mice and in rats, comparing thymosin β4 with a synthetic peptide containing its actin-binding domain.
Analytical chemistry — Belgium

Judák P et al. Anal Biochem. 2017;537:69-71. PMID 28887173 · DOI 10.1016/j.ab.2017.09.003
Laboratory study measuring recovery of four doping-relevant peptides, including TB-500, from different glass and plastic labware surfaces.
In vitro — China (article in Chinese, English abstract)

Li YX et al. Zhongguo Dang Dai Er Ke Za Zhi. 2026;28(7):877-884. PMID 42457332 · DOI 10.7499/j.issn.1008-8830.2512120 (Article in Chinese; English title and abstract)
Cell-culture study of thymosin β4 in mouse BV2 microglial cells in an LPS/nigericin pyroptosis model.
In vitro — China (article in Chinese, English abstract)

Li X et al. Zhonghua Yan Ke Za Zhi. 2013;49(8):716-22. PMID 24246811 (Article in Chinese; English title and abstract)
Primary rabbit corneal epithelial cell cultures exposed to hydrogen peroxide with or without thymosin β4, assessed by viability and apoptosis assays.
Biotechnology — Russia (article in Russian, English abstract)

Beĭrakhova KA et al. Bioorg Khim. 2011;37(2):223-32. PMID 21721255 · DOI 10.1134/s1068162011020026 (Article in Russian; English title and abstract)
Method for producing a recombinant thymosin β4 precursor and converting it to N-terminally acetylated thymosin β4.
Analytical chemistry — Italy

Rossetti DV et al. Electrophoresis. 2013;34(18):2674-82. PMID 23857244 · DOI 10.1002/elps.201300165
Capillary electrophoresis–mass spectrometry method for quantifying thymosin β4 in human whole saliva.
Registered clinical trial — Phase 3

ClinicalTrials.gov · Phase 3 · Completed · first posted 2016. NCT02974907
Registered interventional study (Phase 3); registry status: completed; start 2016-11; locations: United States.
Registered clinical trial — Phase 1

ClinicalTrials.gov · Phase 1 · Completed · first posted 2020. NCT04555824
Registered interventional study (Phase 1); registry status: completed; start 2017-07-17; locations: China.
Registered clinical trial — Phase 2

ClinicalTrials.gov · Phase 2 · Completed · first posted 2009. NCT00832091
Registered interventional study (Phase 2); registry status: completed; start 2006-07; locations: Italy, Poland.

Ipamorelin

Selective pentapeptide growth hormone secretagogue (ghrelin-receptor agonist).

Catalog items: Ipamorelin 10 mg, CJC-1295 (no DAC) / Ipamorelin Blend 10 mg + 10 mg

In vitro + animal (rat, swine)

Raun K et al. Eur J Endocrinol. 1998;139(5):552-61. PMID 9849822 · DOI 10.1530/eje.0.1390552
Pharmacological characterization of the pentapeptide ipamorelin, examining growth hormone release selectivity in primary pituitary cells and in anesthetized rats and conscious swine.
Human — Phase I clinical study

Gobburu JV et al. Pharm Res. 1999;16(9):1412-6. PMID 10496658 · DOI 10.1023/a:1018955126402
Dose-escalation pharmacokinetic/pharmacodynamic modeling study of intravenous infusion in healthy male volunteers, measuring plasma concentrations and growth hormone response.
Animal (rat) — pharmacokinetics

Johansen PB et al. Xenobiotica. 1998;28(11):1083-92. PMID 9879640 · DOI 10.1080/004982598238976
Comparative pharmacokinetic study in male rats of ipamorelin and other peptidyl GH secretagogues across intravenous, oral and nasal routes.
Animal (rat)

Johansen PB et al. Growth Horm IGF Res. 1999;9(2):106-13. PMID 10373343 · DOI 10.1054/ghir.1999.9998
Study in adult female rats examining longitudinal bone growth rate, body weight and growth hormone release over a 15-day administration period.
Animal (rat)

Svensson J et al. J Endocrinol. 2000;165(3):569-77. PMID 10828840 · DOI 10.1677/joe.0.1650569
Study in adult female rats comparing ipamorelin and GHRP-6, examining bone mineral content measured by DEXA.
Animal (rat)

Andersen NB et al. Growth Horm IGF Res. 2001;11(5):266-72. PMID 11735244 · DOI 10.1054/ghir.2001.0239
Adult rat model of glucocorticoid exposure examining bone formation markers and muscle and bone parameters with co-administered ipamorelin.
Animal (rat)

Venkova K et al. J Pharmacol Exp Ther. 2009;329(3):1110-6. PMID 19289567 · DOI 10.1124/jpet.108.149211
Rat model of postoperative ileus examining gastrointestinal transit and food intake after ipamorelin administration.
Human — Phase II randomized trial

Beck DE et al. Int J Colorectal Dis. 2014;29(12):1527-34. PMID 25331030 · DOI 10.1007/s00384-014-2030-8
Proof-of-concept, Phase II, multicenter, double-blind, placebo-controlled study of intravenous ipamorelin in hospital inpatients after small or large bowel resection, examining postoperative ileus measures and safety.
Animal (rat)

Greenwood-Van Meerveld B et al. J Exp Pharmacol. 2012;4:149-55. PMID 27186127 · DOI 10.2147/JEP.S35396
Rat model of postoperative gastric dysmotility examining gastric emptying after ipamorelin administration.
Medicinal chemistry — Denmark

Ankersen M et al. J Med Chem. 1998;41(19):3699-704. PMID 9733495 · DOI 10.1021/jm9801962
Medicinal-chemistry study describing a series of growth hormone secretagogues derived from the ipamorelin structure and their in vitro and in vivo GH-releasing potency.
Animal (rat) + ex vivo — Spain

Jiménez-Reina L et al. Histol Histopathol. 2002;17(3):707-14. PMID 12168778 · DOI 10.14670/HH-17.707
Study of young female rats given ipamorelin, GHRH or saline for 21 days, analyzing pituitary somatotroph cell populations and GH content in cell culture.
Ex vivo (rat tissue) — UAE

Adeghate E et al. Neuro Endocrinol Lett. 2004;25(6):403-6. PMID 15665799
Study of pancreatic tissue fragments from normal and streptozotocin-diabetic rats examining insulin release in response to ipamorelin.
Animal (ferret) — Hong Kong

Lu Z et al. Physiol Behav. 2024;284:114644. PMID 39043357 · DOI 10.1016/j.physbeh.2024.114644
Ferret model of cisplatin-induced emesis comparing the ghrelin-receptor agonists anamorelin and ipamorelin on food intake and body weight.
Animal (rat)

N Mohammadi E et al. J Exp Pharmacol. 2020;12:267-274. PMID 32801950 · DOI 10.2147/JEP.S249747
Rat models of non-inflammatory visceral hypersensitivity and somatic mechanical allodynia comparing ipamorelin with a centrally active ghrelin-receptor agonist.
Animal (fish) — India

Gouda M et al. Anim Reprod Sci. 2024;268:107550. PMID 38996787 · DOI 10.1016/j.anireprosci.2024.107550
21-day study of ipamorelin acetate in tilapia (Oreochromis mossambicus) examining food intake and testicular histology.
Human (single-volunteer metabolism) — Russia

Semenistaya E et al. Drug Test Anal. 2015;7(10):919-25. PMID 25869809 · DOI 10.1002/dta.1787
Anti-doping study identifying urinary metabolites by nano-LC high-resolution mass spectrometry after nasal administration of five GH-releasing peptides, including ipamorelin.
Animal (rat) — Denmark

Aagaard NK et al. Growth Horm IGF Res. 2009;19(5):426-31. PMID 19231263 · DOI 10.1016/j.ghir.2009.01.001
Rat study of prednisolone-induced catabolism comparing ipamorelin and growth hormone on hepatic urea-nitrogen synthesis and nitrogen balance.
Analytical chemistry — Germany

Krug O et al. Growth Horm IGF Res. 2018;41:1-6. PMID 29864719 · DOI 10.1016/j.ghir.2018.05.001
Mass-spectrometric characterization of seized black-market products, identifying a modified GH and glycine-extended GHRP analogues including Gly-ipamorelin.
Analytical chemistry — Hong Kong

Kwok WH et al. Anal Bioanal Chem. 2013;405(8):2595-606. PMID 23318763 · DOI 10.1007/s00216-012-6697-9
LC-MS doping-control method for seven peptides in horse plasma, including ipamorelin, CJC-1295 and the TB-500 sequence, plus their in vitro metabolites.
Registered clinical trial — Phase 2

ClinicalTrials.gov · Phase 2 · Completed · first posted 2008. NCT00672074
Registered interventional study (Phase 2); registry status: completed; start 2008-04; locations: United States.
Registered clinical trial — Phase 2

ClinicalTrials.gov · Phase 2 · Completed · first posted 2011. NCT01280344
Registered interventional study (Phase 2); registry status: completed; start 2011-04; locations: United States.

CJC-1295 (no DAC) / modified GRF(1-29)

Note: the published CJC-1295 clinical literature studied the DAC (drug affinity complex, albumin-binding) form. USAPI supplies CJC-1295 without DAC (tetrasubstituted GRF(1-29)); the no-DAC form appears mainly in analytical and metabolism studies.

Catalog items: CJC-1295 (no DAC) 10 mg, CJC-1295 (no DAC) / Ipamorelin Blend 10 mg + 10 mg

Animal (rat) + in vitro

Jetté L et al. Endocrinology. 2005;146(7):3052-8. PMID 15817669 · DOI 10.1210/en.2004-1286
Chemistry and pharmacology study of maleimide-modified hGRF(1-29) albumin bioconjugates in rats, identifying CJC-1295 (the DAC, albumin-binding form).
Human — randomized clinical trial

Teichman SL et al. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID 16352683 · DOI 10.1210/jc.2005-1536
Two randomized, placebo-controlled, double-blind, ascending-dose trials in healthy adults examining pharmacokinetics, GH and IGF-I levels, and safety of CJC-1295 (DAC form).
Human — clinical study

Ionescu M et al. J Clin Endocrinol Metab. 2006;91(12):4792-7. PMID 17018654 · DOI 10.1210/jc.2006-1702
Study in healthy men using frequent overnight sampling to characterize the pulsatile pattern of GH secretion after CJC-1295 (DAC form) administration.
Human — clinical study (proteomics)

Sackmann-Sala L et al. Growth Horm IGF Res. 2009;19(6):471-7. PMID 19386527 · DOI 10.1016/j.ghir.2009.03.001
Proteomic analysis of serum samples from healthy adults who received CJC-1295 (DAC form), screening for candidate biomarkers of GH/IGF-1 activity.
In vitro (structure–activity)

Cervini LA et al. J Med Chem. 1998;41(5):717-27. PMID 9513600 · DOI 10.1021/jm970618s
Systematic structure–activity relationship scans of hGHRH(1-29)-NH2 amino-acid substitutions, examining receptor potency in vitro; background chemistry for modified GRF(1-29) analogs.
Analytical chemistry

Henninge J et al. Drug Test Anal. 2010;2(11-12):647-50. PMID 21204297 · DOI 10.1002/dta.233
Mass-spectrometric identification of CJC-1295 in a seized, unlabeled pharmaceutical preparation submitted by Norwegian authorities.
Analytical chemistry (in vitro metabolism) — UK

Memdouh S et al. Drug Test Anal. 2021;13(11-12):1871-1887. PMID 34665524 · DOI 10.1002/dta.3183
In vitro metabolism and urine detection study covering sermorelin, tesamorelin, CJC-1295 (no DAC) and CJC-1295 with DAC as separate analytes.
Analytical chemistry — Germany

Knoop A et al. Anal Bioanal Chem. 2016;408(12):3145-53. PMID 26879649 · DOI 10.1007/s00216-016-9377-3
Validated immunoaffinity / mass-spectrometry method for detecting sermorelin, CJC-1293, CJC-1295, tesamorelin and metabolites in human plasma.
Animal (mouse)

Alba M et al. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-4. PMID 16822960 · DOI 10.1152/ajpendo.00201.2006
Study in GHRH-knockout mice examining growth parameters with CJC-1295 (DAC form) given at 24-, 48- and 72-hour intervals.
Analytical chemistry — Australia

Timms M et al. Drug Test Anal. 2019;11(6):804-812. PMID 30489688 · DOI 10.1002/dta.2554
Immuno-PCR screening method for CJC-1295 and other GHRH analogs in equine plasma.
Analytical chemistry — Australia

Timms M et al. Drug Test Anal. 2026. PMID 42876013 · DOI 10.1002/dta.70171
ELISA method using monoclonal antibodies to detect CJC-1295 protein conjugates in equine plasma.
Analytical chemistry — Australia

Timms M et al. Drug Test Anal. 2019;11(8):1248-1257. PMID 30938069 · DOI 10.1002/dta.2599
Validated LC-MS/MS confirmation method for CJC-1295 in equine plasma samples.
Analytical chemistry — Türkiye

Uçaktürk E et al. J Pharm Biomed Anal. 2026;268:117207. PMID 41138283 · DOI 10.1016/j.jpba.2025.117207
Nano-LC quadrupole/Orbitrap mass-spectrometry method for GHRH and its analogues (sermorelin, tesamorelin, CJC-1295) in urine.
Analytical chemistry — Belgium

Coppieters G et al. J Pharm Biomed Anal. 2022;214:114726. PMID 35298973 · DOI 10.1016/j.jpba.2022.114726
Antibody-free ultrafiltration and nanoLC-HRMS/MS assay for GHRH analogues, including CJC-1295, in urine.
Analytical chemistry — Romania

Cristea CD et al. Anal Biochem. 2023;682:115336. PMID 37806509 · DOI 10.1016/j.ab.2023.115336
Weak-cation-exchange SPE with triple-quadrupole UHPLC-MS/MS for detecting GHRH analogues, including CJC-1295, in urine.
Analytical chemistry — Spain

Pont L et al. J Chromatogr A. 2020;1631:461548. PMID 32971474 · DOI 10.1016/j.chroma.2020.461548
Comparison of magnetic-bead surface chemistries for immunopurifying GHRH and its analogues, including CJC-1295, before mass spectrometry.
Registered clinical trial — Phase 2

ClinicalTrials.gov · Phase 2 · Terminated · first posted 2005. NCT00267527
Registered interventional study (Phase 2); registry status: terminated; start 2005-12.

CJC-1295 (no DAC) + Ipamorelin (blend)

No peer-reviewed study or registered trial of this specific combination was found in PubMed, Europe PMC or ClinicalTrials.gov. Studies of each component are listed in their own sections.

Catalog items: CJC-1295 (no DAC) / Ipamorelin Blend 10 mg + 10 mg

MOTS-c

16-amino-acid peptide encoded in the mitochondrial 12S rRNA gene.

Catalog items: MOTS-c 10 mg

In vitro + animal (mouse)

Lee C et al. Cell Metab. 2015;21(3):443-54. PMID 25738459 · DOI 10.1016/j.cmet.2015.02.009
Discovery study identifying MOTS-c, a peptide encoded in mitochondrial 12S rRNA, examining its effects on AMPK signaling in cells and on metabolic parameters in diet-induced obese mice.
In vitro (human cells)

Kim KH et al. Cell Metab. 2018;28(3):516-524.e7. PMID 29983246 · DOI 10.1016/j.cmet.2018.06.008
Cell-based study examining nuclear translocation of MOTS-c under metabolic stress and its interaction with antioxidant-response transcription factors.
Animal (mouse) + human samples

Reynolds JC et al. Nat Commun. 2021;12(1):470. PMID 33473109 · DOI 10.1038/s41467-020-20790-0
Mouse study of physical capacity across ages combined with measurement of circulating and skeletal-muscle MOTS-c levels in humans before and after exercise.
Animal (mouse)

Lu H et al. J Mol Med (Berl). 2019;97(4):473-485. PMID 30725119 · DOI 10.1007/s00109-018-01738-w
Ovariectomized mouse model examining body weight, insulin sensitivity and adipose tissue gene expression with MOTS-c administration.
In vitro + animal (mouse)

Kumagai H et al. iScience. 2024;27(11):111212. PMID 39559755 · DOI 10.1016/j.isci.2024.111212
Cell-free binding assays and mouse experiments examining direct interaction of MOTS-c with the kinase CK2 and skeletal-muscle glucose uptake.
Animal (mouse)

Kumagai H et al. Am J Physiol Endocrinol Metab. 2024;326(3):E207-E214. PMID 38170165 · DOI 10.1152/ajpendo.00285.2023
Mouse hind-limb immobilization model examining skeletal muscle mass and intramuscular lipid infiltration with MOTS-c administration.
Human — observational (China)

Du C et al. Pediatr Diabetes. 2018. PMID 29691953 · DOI 10.1111/pedi.12685
Cross-sectional study measuring circulating MOTS-c levels in obese and normal-weight male children and adolescents in relation to insulin-resistance markers.
Human — observational (Chile)

Cataldo LR et al. J Investig Med. 2018;66(6):1019-1022. PMID 29593067 · DOI 10.1136/jim-2017-000681
Study measuring plasma MOTS-c in lean and obese adults in relation to insulin-sensitivity indices (Matsuda, HOMA-IR).
Human — observational (China)

Qin Q et al. Int J Cardiol. 2018;254:23-27. PMID 29242099 · DOI 10.1016/j.ijcard.2017.12.001
Study of patients undergoing coronary angiography relating circulating MOTS-c levels to coronary endothelial function measurements.
Animal (mouse)

Kim SJ et al. Physiol Rep. 2019;7(13):e14171. PMID 31293078 · DOI 10.14814/phy2.14171
Untargeted plasma metabolomics study in diet-induced obese mice given MOTS-c, examining plasma metabolite profiles and insulin sensitivity.
Analytical chemistry — Germany

Knoop A et al. Rapid Commun Mass Spectrom. 2019;33(4):371-380. PMID 30394592 · DOI 10.1002/rcm.8337
Development of a mass-spectrometry method for detecting the MOTS-c peptide in plasma samples for sports drug testing.
Human — observational (Qatar)

Alser M et al. Rev Cardiovasc Med. 2022;23(5):181. PMID 39077591 · DOI 10.31083/j.rcm2305181
Cross-sectional study comparing serum MOTS-c and humanin levels in professional athletes and non-athlete controls.
Human — observational (New Zealand)

Sequeira IR et al. Biochim Biophys Acta Gen Subj. 2021;1865(11):129991. PMID 34419510 · DOI 10.1016/j.bbagen.2021.129991
Study relating circulating MOTS-c and SHLP2 levels to metabolic syndrome components and depot-specific fat mass (including liver fat) in Chinese and European adults without overt diabetes.
In vitro + animal (mouse) — USA

Rice MC et al. Elife. 2026;12. PMID 42611943 · DOI 10.7554/eLife.87615
Study characterizing MOTS-c as a mitochondrial-encoded cationic peptide, testing antibacterial and immunomodulatory activity in vitro and in mice.
Human — observational (Türkiye)

Kutuk IS et al. Sci Rep. 2026;16(1). PMID 41680431 · DOI 10.1038/s41598-026-39687-x
Study measuring MOTS-c in serum and skeletal muscle of women with polycystic ovary syndrome compared with controls.
Human — cross-sectional (China)

Zhang Z et al. Antioxidants (Basel). 2026;15(10). PMID 42939841 · DOI 10.3390/antiox15101267
Cross-sectional study of serum MOTS-c in elite athletes, recreationally active and sedentary young men in relation to exercise capacity and antioxidant markers.
Animal (rat) — New Zealand

Mills AR et al. Exp Physiol. 2026;111(8):3742-3752. PMID 42321010 · DOI 10.1113/EP093714
Diabetic rat model examining systemic and cardiac inflammasome markers after MOTS-c administration.
In vitro (human cells) — Belgium

Elhusseiny R et al. Physiol Rep. 2026;14(4):e70791. PMID 41732124 · DOI 10.14814/phy2.70791
Primary human skeletal myotubes exposed to dexamethasone with or without MOTS-c or a humanin analogue.
Human — observational (Sweden)

Horwath O et al. Exp Physiol. 2026;111(8):3772-3783. PMID 42349896 · DOI 10.1113/EP093298
Measurement of circulating mitochondrial-derived microproteins, including MOTS-c, at rest and after an acute exercise bout in individuals with cerebral palsy and typically developing controls.
Human — observational (Türkiye)

Filibeli BE et al. Arch Endocrinol Metab. 2026;70(3):e260031. PMID 41945630 · DOI 10.20945/2359-4292-2026-0031
Case-control study of serum MOTS-c levels and the MOTS-c m.1382A>C polymorphism in polycystic ovary syndrome.
Human — observational (China)

Peng L et al. Biomedicines. 2026;14(4). PMID 42072458 · DOI 10.3390/biomedicines14040918
Study relating serum MOTS-c levels to myocardial ischemia-reperfusion injury in patients with acute myocardial infarction.
Registered clinical trial — Phase 1

ClinicalTrials.gov · Phase 1 · Completed · first posted 2019. NCT03998514
Registered interventional study (Phase 1); registry status: completed; start 2018-07-09; locations: United States. CB4211 is a MOTS-c analogue.

NAD+

Nicotinamide adenine dinucleotide. Most human trials study oral NAD+ precursors (nicotinamide riboside, nicotinamide mononucleotide) rather than NAD+ itself; these are labeled 'precursor'.

Catalog items: NAD+ 500 mg

Human — pilot clinical study

Grant R et al. Front Aging Neurosci. 2019;11:257. PMID 31572171 · DOI 10.3389/fnagi.2019.00257
Small pilot study in a human cohort measuring plasma and urine NAD+ metabolome during a 6-hour intravenous NAD+ infusion.
Review article

Verdin E Science. 2015;350(6265):1208-13. PMID 26785480 · DOI 10.1126/science.aac4854
Review of NAD+ biochemistry, including its role as a coenzyme and sirtuin/PARP co-substrate, and age-related changes in NAD+ levels.
Review article

Covarrubias AJ et al. Nat Rev Mol Cell Biol. 2021;22(2):119-141. PMID 33353981 · DOI 10.1038/s41580-020-00313-x
Review of NAD+ biosynthesis, consumption and compartmentalization, and how these processes change during ageing.
Human — randomized crossover trial (precursor)

Martens CR et al. Nat Commun. 2018;9(1):1286. PMID 29599478 · DOI 10.1038/s41467-018-03421-7
Randomized, double-blind, placebo-controlled crossover trial in healthy middle-aged and older adults of the NAD+ precursor nicotinamide riboside, measuring tolerability and blood NAD+ levels.
Human — randomized controlled trial (precursor)

Yoshino M et al. Science. 2021;372(6547):1224-1229. PMID 33888596 · DOI 10.1126/science.abe9985
10-week randomized, placebo-controlled, double-blind trial of the NAD+ precursor nicotinamide mononucleotide in postmenopausal women with prediabetes, measuring insulin sensitivity by clamp.
Human — randomized controlled trial (precursor)

Pencina KM et al. J Clin Endocrinol Metab. 2023;108(8):1968-1980. PMID 36740954 · DOI 10.1210/clinem/dgad027
Randomized, placebo-controlled physiologic study of an oral nicotinamide mononucleotide formulation in overweight or obese adults aged 45+, measuring safety and blood NAD levels.
Human — randomized controlled trial (China)

Yu X et al. Am J Cardiovasc Drugs. 2026. PMID 42961639 · DOI 10.1007/s40256-026-00826-4
Prospective randomized, placebo-controlled trial in 120 STEMI patients undergoing primary PCI evaluating intravenous NAD+ as an adjunct, with LVEF at 30 days as the primary endpoint.
Human — retrospective review (NAD+ IV)

Reyna K et al. Front Aging. 2026;7:1652582. PMID 41704678 · DOI 10.3389/fragi.2026.1652582
Retrospective review of records from a commercial setting comparing infusion time, tolerability and safety markers for intravenous NAD+ versus intravenous nicotinamide riboside.
In vitro + animal (mouse)

Pillai VB et al. J Biol Chem. 2010;285(5):3133-44. PMID 19940131 · DOI 10.1074/jbc.M109.077271
Cardiomyocyte and mouse study (including SIRT3/SIRT1 knockout and transgenic models) examining exogenous NAD and agonist-induced cardiac hypertrophy signaling.
Animal (rat)

Ying W et al. Front Biosci. 2007;12:2728-34. PMID 17127275 · DOI 10.2741/2267
Rat model of transient focal cerebral ischemia examining intranasal NAD+ administration and infarct measures.
Animal (rat) — China

Zhang YJ et al. Basic Res Cardiol. 2020;115(5):57. PMID 32778948 · DOI 10.1007/s00395-020-0817-z
Rat model of myocardial ischemia/reperfusion examining coronary microvascular measures after NAD+ administration.
In vitro — Italy

Pittelli M et al. Mol Pharmacol. 2011;80(6):1136-46. PMID 21917911 · DOI 10.1124/mol.111.073916
Cell-line and primary-culture study examining uptake of exogenous NAD, mitochondrial bioenergetics, DNA repair and apoptosis.
In vitro — China

Zhu Y et al. Sci Rep. 2016;6:26322. PMID 27240523 · DOI 10.1038/srep26322
Cell-culture study of retinal pigment epithelium cells under hydrogen-peroxide oxidative stress examining exogenous NAD+.
Animal (rat) — China

Su C et al. Crit Care Med. 2022;50(2):e189-e198. PMID 34637412 · DOI 10.1097/CCM.0000000000005268
Rat cardiac-arrest and resuscitation model comparing exogenous NAD with control on post-resuscitation myocardial and neurological measures.
In vitro (human cells) — USA

Li G et al. HIV Med. 2026. PMID 42972877 · DOI 10.1111/hiv.70342
T cells from people with HIV cultured with NAD+ in vitro, examining CD4+ and CD8+ T-cell function.
Animal (rodent) — USA

Goodnough CL et al. Sci Rep. 2025;15(1):1428. PMID 39789056 · DOI 10.1038/s41598-024-83500-6
Rodent study testing whether NAD+ supplementation changes recovery from general anesthesia.
Animal (mouse) — China

Song S et al. Brain Behav. 2025;15(5):e70525. PMID 40320991 · DOI 10.1002/brb3.70525
Cuprizone-induced demyelination mouse model with NAD+ supplementation, examining behavioral measures.
Animal (mouse) — USA

Okur MN et al. Aging Cell. 2023;22(9):e13909. PMID 37395319 · DOI 10.1111/acel.13909
Long-term NAD+ supplementation study in mice examining age-related hearing loss measures.
Human — case report (Lebanon)

Itani MR et al. ACR Open Rheumatol. 2026;8(9):e90151. PMID 42751848 · DOI 10.1002/acr2.90151
Single case report of a patient with rheumatoid arthritis followed clinically and by ultrasonography during intravenous NAD+.
Registered clinical trial — Phase 1/Phase 2

ClinicalTrials.gov · Phase 1/Phase 2 · Recruiting · first posted 2025. NCT06776510
Registered interventional study (Phase 1/Phase 2); registry status: recruiting; start 2025-01-15; locations: China.
Registered clinical trial — Phase 2

ClinicalTrials.gov · Phase 2 · Not yet recruiting · first posted 2026. NCT07839130
Registered interventional study (Phase 2); registry status: not yet recruiting; start 2026-10-01; locations: China.

PT-141 (Bremelanotide)

Cyclic heptapeptide melanocortin receptor agonist.

Catalog items: PT-141 (Bremelanotide) 10 mg

Animal (rat)

Pfaus JG et al. Proc Natl Acad Sci U S A. 2004;101(27):10201-4. PMID 15226502 · DOI 10.1073/pnas.0400491101
Female rat behavioral study examining solicitational and other sexual behaviors after administration of the melanocortin receptor agonist PT-141.
Human — Phase I clinical trial

Diamond LE et al. Int J Impot Res. 2004;16(1):51-9. PMID 14963471 · DOI 10.1038/sj.ijir.3901139
Double-blind, placebo-controlled Phase I study of intranasal PT-141 in healthy men assessing safety, pharmacokinetics and erectile response measured by RigiScan.
Human — Phase I/II clinical trial

Rosen RC et al. Int J Impot Res. 2004;16(2):135-42. PMID 14999221 · DOI 10.1038/sj.ijir.3901200
Placebo-controlled study of subcutaneous PT-141 in healthy men and in men with erectile dysfunction, assessing safety, pharmacokinetics and erectile response.
Human — randomized crossover trial

Diamond LE et al. Urology. 2005;65(4):755-9. PMID 15833522 · DOI 10.1016/j.urology.2004.10.060
Randomized crossover study in men with erectile dysfunction examining co-administration of intranasal PT-141 with sildenafil versus sildenafil alone or placebo.
Human — Phase III clinical trials

Kingsberg SA et al. Obstet Gynecol. 2019;134(5):899-908. PMID 31599840 · DOI 10.1097/AOG.0000000000003500
Two identical randomized, double-blind, placebo-controlled 24-week Phase III trials (RECONNECT) of bremelanotide in premenopausal women with hypoactive sexual desire disorder.
Human — open-label extension

Simon JA et al. Obstet Gynecol. 2019;134(5):909-917. PMID 31599847 · DOI 10.1097/AOG.0000000000003514
52-week open-label extension of the RECONNECT Phase III trials describing long-term safety and questionnaire outcomes in premenopausal women.
Human — Phase I clinical trial

Clayton AH et al. Clin Ther. 2017;39(3):514-526.e14. PMID 28189361 · DOI 10.1016/j.clinthera.2017.01.018
Randomized, placebo-controlled, double-blind crossover Phase I study in healthy adults examining safety, hemodynamics and pharmacokinetics of bremelanotide co-administered with ethanol.
Human — two Phase I randomized trials

Spana C et al. Diabetes Obes Metab. 2022;24(6):1084-1093. PMID 35170192 · DOI 10.1111/dom.14672
Two single-centre, randomized, double-blind, placebo-controlled Phase I trials of bremelanotide in premenopausal women with obesity, examining caloric intake and body weight.
Human — Phase III subgroup analysis

Simon JA et al. J Womens Health (Larchmt). 2022;31(3):391-400. PMID 35230162 · DOI 10.1089/jwh.2021.0225
Prespecified and integrated subgroup analyses of the two RECONNECT Phase III trials of bremelanotide.
Human — safety review (Phases 1–3)

Clayton AH et al. J Womens Health (Larchmt). 2022;31(2):171-182. PMID 35147466 · DOI 10.1089/jwh.2021.0191
Review of bremelanotide safety data from Phase 1 through Phase 3 of its clinical development program.
Analytical chemistry — India

Yuvaraaj VK et al. Anal Methods. 2026;18(32):6968-6982. PMID 42485063 · DOI 10.1039/d6ay01098a
Stability-indicating RP-HPLC method and LC-HRMS/MS characterization of bremelanotide acetate degradation products.
Analytical chemistry — Italy

Mestria S et al. Drug Test Anal. 2021;13(4):876-882. PMID 33245851 · DOI 10.1002/dta.2986
LC-HRMS characterization of melanotan II and bremelanotide in products sold on the black market.
In vitro — Japan

Suzuki S et al. Anticancer Res. 2024;44(9):3875-3883. PMID 39197897 · DOI 10.21873/anticanres.17214
Glioblastoma and normal human cell cultures exposed to bremelanotide, examining cell death and survivin expression.
Human — re-analysis of Phase III trials

Spielmans GI J Sex Res. 2021;58(9):1085-1105. PMID 33678061 · DOI 10.1080/00224499.2021.1885601
Independent re-analysis of reporting in the two Phase III bremelanotide trials against the registered study protocols.
Registered clinical trial — Phase 3

ClinicalTrials.gov · Phase 3 · Completed · first posted 2021. NCT04943068
Registered interventional study (Phase 3); registry status: completed; start 2021-05-10; locations: South Korea.
Registered clinical trial — Phase 4

ClinicalTrials.gov · Phase 4 · Completed · first posted 2019. NCT04179734
Registered interventional study (Phase 4); registry status: completed; start 2019-10-07; locations: United Kingdom.

Semaglutide

Acylated GLP-1 receptor agonist peptide.

Catalog items: Semaglutide 10 mg

Medicinal chemistry + animal

Lau J et al. J Med Chem. 2015;58(18):7370-80. PMID 26308095 · DOI 10.1021/acs.jmedchem.5b00726
Medicinal-chemistry study describing the design of semaglutide (fatty-acid acylation, Aib substitution), receptor potency, albumin binding and pharmacokinetics in animals.
Human — randomized controlled trial

Marso SP et al. N Engl J Med. 2016;375(19):1834-1844. PMID 27633186 · DOI 10.1056/NEJMoa1607141
SUSTAIN-6: randomized, double-blind, placebo-controlled trial in adults with type 2 diabetes at high cardiovascular risk evaluating major adverse cardiovascular events.
Human — randomized controlled trial

Husain M et al. N Engl J Med. 2019;381(9):841-851. PMID 31185157 · DOI 10.1056/NEJMoa1901118
PIONEER 6: randomized, double-blind, placebo-controlled trial of oral semaglutide in adults with type 2 diabetes evaluating cardiovascular safety.
Human — randomized controlled trial

Wilding JPH et al. N Engl J Med. 2021;384(11):989-1002. PMID 33567185 · DOI 10.1056/NEJMoa2032183
STEP 1: 68-week randomized, double-blind, placebo-controlled trial in adults with overweight or obesity without diabetes, evaluating change in body weight.
Human — randomized controlled trial

Lincoff AM et al. N Engl J Med. 2023;389(24):2221-2232. PMID 37952131 · DOI 10.1056/NEJMoa2307563
SELECT: randomized, double-blind, placebo-controlled trial in adults with established cardiovascular disease and overweight or obesity without diabetes, evaluating cardiovascular events.
Human — randomized controlled trial

Perkovic V et al. N Engl J Med. 2024;391(2):109-121. PMID 38785209 · DOI 10.1056/NEJMoa2403347
FLOW: randomized, double-blind, placebo-controlled trial in adults with type 2 diabetes and chronic kidney disease evaluating kidney outcome events.
Human — randomized controlled trial

Kosiborod MN et al. N Engl J Med. 2023;389(12):1069-1084. PMID 37622681 · DOI 10.1056/NEJMoa2306963
STEP-HFpEF: randomized, double-blind, placebo-controlled trial in adults with heart failure with preserved ejection fraction and obesity, evaluating symptom scores and body weight.
Human — randomized controlled trial (multinational)

Sorli C et al. Lancet Diabetes Endocrinol. 2017;5(4):251-260. PMID 28110911 · DOI 10.1016/S2213-8587(17)30013-X
SUSTAIN 1: 30-week randomized, double-blind, placebo-controlled Phase III trial of semaglutide monotherapy in adults with type 2 diabetes at 72 sites in nine countries including Canada, Italy, Japan, Mexico, Russia, South Africa and the UK.
Human — randomized controlled trial (multinational)

Davies M et al. Lancet. 2021;397(10278):971-984. PMID 33667417 · DOI 10.1016/S0140-6736(21)00213-0
STEP 2: 68-week randomized, double-blind Phase III trial in adults with overweight or obesity and type 2 diabetes at 149 clinics in 12 countries, evaluating body weight.
Human — Phase III randomized trial (China; article in Chinese, English abstract)

Wang WM et al. Zhonghua Yi Xue Za Zhi. 2026;106(41):4501-4512. PMID 42933873 · DOI 10.3760/cma.j.cn112137-20260717-01789 (Article in Chinese; English title and abstract)
Multicenter, randomized, positive-controlled Phase III equivalence trial of a domestically produced semaglutide injection at 39 centers in China in adults with type 2 diabetes on metformin.
Human — prospective study (Russia)

Tyurina AV et al. Kardiologiia. 2026;66(2):31-40. PMID 41925173 · DOI 10.18087/cardio.2026.2.n3116 (Article in Russian; English title and abstract)
Eight-month study of semaglutide in 65 adults with obesity with or without type 2 diabetes, measuring anthropometrics, blood lipids and adipokines. Published in Kardiologiia (Moscow).
Human — non-randomized controlled study (China; article in Chinese, English abstract)

Niu S et al. Zhonghua Nei Ke Za Zhi. 2025;64(12):1218-1225. PMID 41338557 · DOI 10.3760/cma.j.cn112138-20250424-00235 (Article in Chinese; English title and abstract)
Prospective non-randomized study of serum metabolomics in adults with obesity, type 2 diabetes and metabolic-associated fatty liver disease given semaglutide.
Human — comparative study (Spain; article in Spanish, English abstract)

Pujol Calafat A et al. Nutr Hosp. 2024;41(6):1224-1230. PMID 39512012 · DOI 10.20960/nh.05244 (Article in Spanish; English title and abstract)
Comparative study of semaglutide 0.5 mg weekly versus liraglutide 3 mg daily on anthropometric measures in adults with obesity.
Human — randomized controlled trial

Tuttle KR et al. Nat Med. 2026;32(11):4307-4318. PMID 42823485 · DOI 10.1038/s41591-026-04674-2
52-week randomized, placebo-controlled trial of semaglutide 1 mg weekly in 106 adults with type 2 diabetes and chronic kidney disease, including kidney transcriptomic outcomes.
Human — randomized controlled trial (UK)

Stanley C et al. Nat Med. 2026;32(7):2662-2672. PMID 42174253 · DOI 10.1038/s41591-026-04416-4
Double-blind, randomized, placebo-controlled trial (BARI-STEP) of semaglutide 2.4 mg in adults with suboptimal weight loss at least one year after bariatric surgery.
Human — secondary analysis of RCT (adolescents)

Arslanian S et al. Diabetes Care. 2026;49(6):954-962. PMID 41296499 · DOI 10.2337/dc25-0824
Secondary analysis of the STEP TEENS Phase 3a trial examining insulin sensitivity and cardiometabolic risk factors in adolescents aged 12 to under 18.
Human — Phase III randomized trial (Japan, South Korea)

Kadowaki T et al. JAMA Intern Med. 2025;185(10):1206-1217. PMID 40758358 · DOI 10.1001/jamainternmed.2025.3599
OASIS 2: 68-week double-blind, placebo-controlled Phase 3a trial of oral semaglutide in East Asian adults with overweight or obesity, with or without type 2 diabetes.
Human — Phase III randomized trial (China)

Wang W et al. Diabetologia. 2024;67(9):1783-1799. PMID 38985162 · DOI 10.1007/s00125-024-06142-3
PIONEER 11: double-blind, randomized Phase III trial of oral semaglutide monotherapy versus placebo in a predominantly Chinese population with type 2 diabetes.

Tirzepatide

Dual GIP / GLP-1 receptor agonist peptide (LY3298176).

Catalog items: Tirzepatide 10 mg

In vitro + animal + human Phase I

Coskun T et al. Mol Metab. 2018;18:3-14. PMID 30473097 · DOI 10.1016/j.molmet.2018.09.009
Discovery study of LY3298176 (tirzepatide) characterizing dual GIP/GLP-1 receptor activity in cell assays and mice, with Phase I studies in healthy subjects and type 2 diabetes.
Human — randomized controlled trial

Rosenstock J et al. Lancet. 2021;398(10295):143-155. PMID 34186022 · DOI 10.1016/S0140-6736(21)01324-6
SURPASS-1: 40-week randomized, double-blind, placebo-controlled Phase III trial in adults with type 2 diabetes managed with diet and exercise alone, evaluating HbA1c.
Human — randomized controlled trial

Frías JP et al. N Engl J Med. 2021;385(6):503-515. PMID 34170647 · DOI 10.1056/NEJMoa2107519
SURPASS-2: 40-week open-label randomized Phase III trial comparing tirzepatide with semaglutide in adults with type 2 diabetes on metformin, evaluating HbA1c.
Human — randomized controlled trial

Jastreboff AM et al. N Engl J Med. 2022;387(3):205-216. PMID 35658024 · DOI 10.1056/NEJMoa2206038
SURMOUNT-1: 72-week randomized, double-blind, placebo-controlled Phase III trial in adults with obesity or overweight without diabetes, evaluating body weight.
Human — randomized controlled trials

Malhotra A et al. N Engl J Med. 2024;391(13):1193-1205. PMID 38912654 · DOI 10.1056/NEJMoa2404881
SURMOUNT-OSA: two randomized, double-blind, placebo-controlled Phase III trials in adults with obstructive sleep apnea and obesity, evaluating apnea–hypopnea index.
Human — randomized controlled trial

Packer M et al. N Engl J Med. 2025;392(5):427-437. PMID 39555826 · DOI 10.1056/NEJMoa2410027
SUMMIT: randomized, double-blind, placebo-controlled trial in adults with heart failure with preserved ejection fraction and obesity, evaluating cardiovascular events and symptom scores.
Human — randomized controlled trial

Loomba R et al. N Engl J Med. 2024;391(4):299-310. PMID 38856224 · DOI 10.1056/NEJMoa2401943
SYNERGY-NASH: Phase II randomized, double-blind, placebo-controlled trial in adults with biopsy-confirmed MASH and liver fibrosis, evaluating liver histology.
Human — randomized controlled trial (multinational)

Garvey WT et al. Lancet. 2023;402(10402):613-626. PMID 37385275 · DOI 10.1016/S0140-6736(23)01200-X
SURMOUNT-2: 72-week randomized, double-blind, placebo-controlled Phase III trial in adults with obesity and type 2 diabetes, evaluating body weight.
Human — randomized controlled trial

Wadden TA et al. Nat Med. 2023;29(11):2909-2918. PMID 37840095 · DOI 10.1038/s41591-023-02597-w
SURMOUNT-3: randomized, double-blind, placebo-controlled trial in adults with obesity after a 12-week intensive lifestyle run-in, evaluating additional weight change.
Systematic review — Cochrane

Franco JV et al. Cochrane Database Syst Rev. 2025;10(10):CD016018. PMID 41161687 · DOI 10.1002/14651858.CD016018
Cochrane systematic review and meta-analysis of randomized trials of tirzepatide in adults living with obesity.
Human — real-world cohort (Spain; article in Spanish, English abstract)

Blanco Anesto J et al. Nutr Hosp. 2026;43(6):1270-1275. PMID 42037504 · DOI 10.20960/nh.06592 (Article in Spanish; English title and abstract)
Retrospective real-world cohort of 52 adults with obesity on tirzepatide, measuring body composition by bioimpedance and handgrip muscle function.
Human — RCT subpopulation analysis (Japan)

Ishigaki Y et al. Obesity (Silver Spring). 2026;34(3):608-621. PMID 41612966 · DOI 10.1002/oby.70131
Prespecified analysis of the 102 Japanese participants in the SURMOUNT-1 trial of tirzepatide versus placebo.
Human — randomized trial (China)

Yang Z et al. Diabetes Obes Metab. 2026;28(8):7380-7392. PMID 42236268 · DOI 10.1111/dom.70966
Randomized study in 60 Chinese women with overweight or obesity and polycystic ovary syndrome comparing low-dose tirzepatide plus metformin with metformin alone.
Human — genetic analysis of RCT participants

Bhatnagar P et al. Nat Med. 2025;31(10):3294-3296. PMID 40858971 · DOI 10.1038/s41591-025-03913-2
Analysis of SURMOUNT-1 participants carrying MC4R variants compared with non-carriers on tirzepatide.
Human — Phase IV randomized trial

Del Prato S et al. Ann Intern Med. 2026;179(7):917-928. PMID 42184419 · DOI 10.7326/ANNALS-25-05602
SURPASS-EARLY: 2-year randomized, open-label Phase 4 trial of tirzepatide versus intensified conventional care in early type 2 diabetes.
Human — pragmatic trial design (UK)

Rutter MK et al. Obesity (Silver Spring). 2026;34(11):2051-2060. PMID 42297568 · DOI 10.1002/oby.70247
Design of SURMOUNT-REAL UK, a 5-year pragmatic randomized trial of tirzepatide plus standard care versus standard care using electronic health records in Greater Manchester.
Human — RCT post hoc analysis (China)

Zhao L et al. Obesity (Silver Spring). 2025;33(7):1287-1296. PMID 40437798 · DOI 10.1002/oby.24306
Post hoc subgroup analysis of the SURMOUNT-CN trial in Chinese adults, examining body weight and cardiometabolic markers by baseline BMI.

Retatrutide

Triple glucagon / GIP / GLP-1 receptor agonist peptide (LY3437943).

Catalog items: Retatrutide 10 mg

In vitro + animal + human Phase I

Coskun T et al. Cell Metab. 2022;34(9):1234-1247.e9. PMID 35985340 · DOI 10.1016/j.cmet.2022.07.013
Discovery study of LY3437943 (retatrutide) characterizing glucagon/GIP/GLP-1 receptor activity in vitro and in obese mice, with a Phase I single-dose study in healthy subjects.
Human — Phase Ib clinical trial

Urva S et al. Lancet. 2022;400(10366):1869-1881. PMID 36354040 · DOI 10.1016/S0140-6736(22)02033-5
Randomized, double-blind, placebo-controlled multiple-ascending-dose Phase Ib study in people with type 2 diabetes assessing safety, pharmacokinetics and pharmacodynamics.
Human — Phase II clinical trial

Jastreboff AM et al. N Engl J Med. 2023;389(6):514-526. PMID 37366315 · DOI 10.1056/NEJMoa2301972
48-week randomized, double-blind, placebo-controlled Phase II trial in adults with obesity or overweight, evaluating change in body weight.
Human — Phase II clinical trial

Rosenstock J et al. Lancet. 2023;402(10401):529-544. PMID 37385280 · DOI 10.1016/S0140-6736(23)01053-X
36-week randomized, double-blind, placebo- and active-controlled Phase II trial in adults with type 2 diabetes conducted in the USA, evaluating HbA1c and body weight.
Human — Phase IIa substudy

Sanyal AJ et al. Nat Med. 2024;30(7):2037-2048. PMID 38858523 · DOI 10.1038/s41591-024-03018-2
Randomized, double-blind, placebo-controlled substudy of the Phase II obesity trial in participants with metabolic dysfunction-associated steatotic liver disease, evaluating liver fat by MRI.
Human — Phase III clinical trial

Jastreboff AM et al. N Engl J Med. 2026;395(18):1781-1793. PMID 42814954 · DOI 10.1056/NEJMoa2604169
Phase III randomized, double-blind, placebo-controlled 80-week trial in adults with obesity without diabetes, evaluating body weight and knee osteoarthritis pain scores.
Human — Phase III clinical trial

Bellido V et al. Lancet. 2026;408(10563):1455-1472. PMID 42810372 · DOI 10.1016/S0140-6736(26)01861-1
TRIUMPH-2: Phase III randomized, double-blind, placebo-controlled trial in adults with obesity and type 2 diabetes at 92 centers in eight countries.
Human — Phase III randomized trials

Schnitzer TJ et al. N Engl J Med. 2026. PMID 43001755 · DOI 10.1056/NEJMoa2610676
TRIUMPH-4 and TRIUMPH-1-OA: Phase 3 randomized, placebo-controlled trials of once-weekly retatrutide in adults with knee osteoarthritis pain and BMI of 27 or more.
Human — Phase III randomized trials

Grunstein RR et al. N Engl J Med. 2026. PMID 42904878 · DOI 10.1056/NEJMoa2611477
Two Phase 3 double-blind, placebo-controlled trials nested in TRIUMPH basket trials, in adults with moderate-to-severe obstructive sleep apnea.
Human — Phase III randomized trial (USA, Mexico, India)

Bajaj HS et al. Lancet. 2026;407(10546):2402-2413. PMID 42250575 · DOI 10.1016/S0140-6736(26)00967-0
40-week Phase 3 randomized, double-blind, placebo-controlled trial of retatrutide in adults with type 2 diabetes managed by diet and exercise, at 48 sites in the USA, Mexico and India.
Human — post hoc analysis of Phase II RCTs

Ruotolo G et al. Diabetes Obes Metab. 2026;28(11):10183-10194. PMID 42608321 · DOI 10.1111/dom.71200
Post hoc analysis of lipoprotein and inflammatory biomarkers in two Phase 2 randomized, placebo-controlled trials of retatrutide.
Human — post hoc analysis of Phase II RCTs

Pearson MJ et al. J Clin Endocrinol Metab. 2026;111(11):3217-3228. PMID 42135195 · DOI 10.1210/clinem/dgag201
Exploratory metabolomics and lipidomics of fasting samples from two Phase 2 randomized, placebo-controlled retatrutide trials.
Analytical chemistry — Brazil

Carneiro GRA et al. Rapid Commun Mass Spectrom. 2026;40(23):e70179. PMID 42745421 · DOI 10.1002/rcm.70179
LC-HRMS method for detecting retatrutide in human plasma and urine and describing its excretion profile for anti-doping analysis.
Ex vivo (human atrial tissue) — Germany

Neumann J et al. Naunyn Schmiedebergs Arch Pharmacol. 2026;399(1):317-327. PMID 40613938 · DOI 10.1007/s00210-025-04421-3
Isolated human right-atrial preparations from cardiac surgery patients, examining force of contraction in response to retatrutide.
Animal (rat) — Türkiye

Keskin U et al. J Mol Histol. 2026;57(6). PMID 42878930 · DOI 10.1007/s10735-026-11013-9
Streptozotocin-induced diabetic rat model examining renal inflammatory cytokines, HIF-1α expression and histology with retatrutide.
Registered clinical trial — Phase 3

ClinicalTrials.gov · Phase 3 · Active not recruiting · first posted 2024. NCT06662383
Registered interventional study (Phase 3); registry status: active not recruiting; start 2024-11-01; locations: Argentina, Germany, Poland, Puerto Rico, United States.
Registered clinical trial — Phase 3

ClinicalTrials.gov · Phase 3 · Active not recruiting · first posted 2024. NCT06383390
Registered interventional study (Phase 3); registry status: active not recruiting; start 2024-04-30; locations: Argentina, Australia, Austria, Belgium, Brazil, Canada and others.

Citation details (title, first author, journal, year, PMID, DOI, registry ID) were retrieved from PubMed / NCBI, Europe PMC and ClinicalTrials.gov and cross-checked against Crossref or the publisher record. Non-English articles are listed under their English titles. Study descriptions summarize design only and are not statements about any USAPI product. USAPI products are sold strictly for in-vitro laboratory research by qualified researchers aged 21+.